Exploring the Interest and Intention to Use Long-Acting Injectable PrEP (LAI-PrEP) Among Gay, Bisexual and Other Men
Johann Kolstee1, Haoyi Wang2, Hanne Zimmermann2
1Faculty of Psychology and Neuroscience - Maastricht, Maastricht University, Universiteitssingel 40, PO Box 616, 6200 MD, Maastricht, The Netherlands. johann.kolstee@maastrichtuniversity.nl.
Abstract:
Long-acting injectable PrEP (LAI-PrEP) provides opportunities to expand HIV prevention coverage in the Netherlands. Understanding which Dutch gay, bisexual and other men who have sex with men (GBMSM) are interested in using LAI-PrEP when available can support HIV prevention efforts. Survey data was collected online via the PROTECT survey from 1,447 GBMSM in the Netherlands between October 2023 and March 2024. Multivariable logistic analysis was conducted to determine variables associated with GBMSM who intend to use LAI-PrEP when available. Interest and intention to use LAI-PrEP among Dutch GBMSM is high (76.1% and 73.9%) and among those currently on oral PrEP even higher (80.8% and 79.5%). GBMSM who intend to use LAI-PrEP have more sexual partners in the past 6 months (11-50 partners (aOR = 3.24; 95%CI: 1.54-6.85), 51-100 partners (aOR = 3.10; 95% CI: 1.20 to 8.30), more than 150 partners (aOR = 3.86; 95% CI: 1.74 to 8.67)), engage more in chemsex (aOR = 1.41; 95% CI: 1.00 to 2.01), are less likely to fear LAI-PrEP side effects (aOR = 0.83; 95% CI: 0.74 to 0.94;) or injection pain (aOR = 0.68; 95% CI: 0.61 to 0.75) and more likely to believe they are at risk of acquiring HIV (aOR = 1.23; 95% CI: 1.05 to 1.45). If made available in the Netherlands, many GBMSM are likely to commence using LAI-PrEP, particularly current oral PrEP users or discontinued users. Sexually active Dutch GBMSM, who are already protecting themselves, may be the first group to use LAI-PrEP.
Related Concept Videos
Gas Laws: Boyle's, Gay-Lussac, Charles', Avogadro's, and Ideal Gas Law
Forces Acting on Chromosomes
Microtubules and motor proteins exert two types of forces on...
Sex-linked Disorders
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Drugs Acting on Autonomic Ganglia: Blockers


